```markdown
| Country      | Comparator         | Population details                                                                 |
|--------------|---------------------|------------------------------------------------------------------------------------|
| Netherlands  | Sotorasib           | Patients with KRAS G12C-mutated advanced NSCLC who had disease progression after previous platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. |
| Netherlands  | Docetaxel           | Patients with KRAS G12C-mutated advanced NSCLC who had disease progression after previous platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. |
```